DES in critical ischemia caused by infrapopliteal lesions

Original Title: Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial.
Reference: Marlon I. Spreen et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002376.

 

The treatment of infrapopliteal lesions in patients with critical limb ischemia is limited by the high rates of restenosis. The most frequent course of treatment is PCI with balloon and conventional bare metal stents (BMS), only for dissections compromising flow. This multicenter randomized study was promoted by researchers to assess whether DES could improve patency and clinical outcomes of PCI in infrapopliteal lesions.

This study randomized patients with critical ischemia (Rutherford ≥4) and infrapopliteal lesions to PCI with balloon and bail-out BMS vs. paclitaxel eluting DES.

Primary end point was binary restenosis at 6 months assessed by CT angiography. A >50% stenosis, reintervention, major amputation or treatment related death were deemed treatment failure.

73 patients were treated with DES and 64 patients were treated with balloon ± BMS. Patency at 6 months was 48% with DES and 35% with balloon ± BMS (p=0.096).

Major amputation rate was low in the DES group, even two years after procedure, with a tendency to be lower than in the balloon ± BMS group.
Minor amputations rate at 6 months was indeed significant, in favor of the DES group (P=0.03).

Conclusion
In patients with critical limb ischemia caused by infrapopliteal lesions, DES are associated with better patency at 6 months and a lower amputations rate at 6 months and one year, compared with the strategy of PCI with balloon and bailout BMS.

More articles by this author

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...